Article ; Online: Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
2021 Volume 71, Page(s) 103519
Abstract: ... investigated neutralisation titres against SARS-CoV-2 up to 6 months post-symptom onset in individuals ... determined at baseline and 6 months post-symptom onset using a cell culture infectious SARS-CoV-2 assay ... 19 individuals were found to have detectable SARS-CoV-2 50% inhibitory dilution neutralisation titres ...
| Abstract | Background: Given the importance of neutralising antibodies in protection against SARS-CoV-2 infection, it is critical to assess neutralisation persistence long-term following recovery. This study investigated neutralisation titres against SARS-CoV-2 up to 6 months post-symptom onset in individuals with mild COVID-19. Methods: Plasma neutralisation titres in convalescent COVID-19 individuals were determined at baseline and 6 months post-symptom onset using a cell culture infectious SARS-CoV-2 assay. Total SARS-CoV-2 spike-specific IgG and IgA binding was measured using a lectin capture ELISA and compared between timepoints and correlated to neutralising titres. Findings: All 48 convalescent COVID-19 individuals were found to have detectable SARS-CoV-2 50% inhibitory dilution neutralisation titres (ID Interpretation: This study demonstrates durability of SARS-CoV-2 spike-specific IgG and neutralisation responses following recovery from mild COVID-19. Thus, all subjects included in this study might potentially have protective levels of neutralising antibodies 6 months post-symptom onset. This study also demonstrates a relationship between spike-specific IgA and neutralisation decline, with implications for long-term protection against SARS-CoV-2 infection. Funding: Novo Nordisk Foundation, Independent Research Fund Denmark and Danish Agency for Science and Higher Education. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19/epidemiology ; COVID-19/immunology ; COVID-19/virology ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Immunoglobulin A/immunology ; Immunoglobulin G/immunology ; Male ; Middle Aged ; SARS-CoV-2/pathogenicity | |||||
| Chemical Substances | Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin A ; Immunoglobulin G | |||||
| Language | English | |||||
| Publishing date | 2021-08-19 | |||||
| Publishing country | Netherlands | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 2851331-9 | |||||
| ISSN | 2352-3964 | |||||
| ISSN (online) | 2352-3964 | |||||
| DOI | 10.1016/j.ebiom.2021.103519 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 7090: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.